A potent and covalent BTK inhibitor 1 mg


≥98% pure A potent and covalent BTK inhibitor 1 mg



Thymosin α1 is an immunomodulator peptide formed from the cleavage of prothymosin α.1 Thymosin α1 inhibits the growth of 5TGM1 mouse and OPM-2, LP-1, and U266 human multiple myeloma cells in vitro but not in vivo.2 It also increases CD3- and CD28-induced T cell proliferation in C57BL/KaLwRij splenocytes but not in allogeneic mixed lymphocyte reactions using C57BL/KaLwRij and BALB/c splenocyte co-cultures when used at a concentration of 20 μM. Thymosin α1 also inhibits the growth and migration of H1299, NL9980, and L9981 non-small cell lung cancer (NSCLC) cells that express high levels of programmed cell death ligand 1 (PD-L1) but not of A549 and SPC-A-1 NSCLC cells that express low PD-L1 levels.3 It also decreases the number of metastatic lesions in a L9981, but not an A549, NSCLC mouse xenograft model when administered at a dose of 20 mg/kg per day. Thymosin α1 (200 μg/kg) increases indoleamine 2,3-dioxygenase 1 (IDO1) expression and IL-10 levels and decreases IL-1β and TNF-α production in the lung in a p.Phe508del mutant cystic fibrosis transmembrane conductance regulator (CFTRF508del/F508del) mouse model of cystic fibrosis and chronic A. fumigatus infection.4WARNING This product is not for human or veterinary use.


There are no reviews yet.

Be the first to review “A potent and covalent BTK inhibitor 1 mg”

Your email address will not be published. Required fields are marked *

Got something to discuss?